Deals this week: Loxo Oncology, Merit Medical Systems, BioMaxima

23 March 2017 (Last Updated March 23rd, 2017 18:30)

Loxo Oncology and Ventana Medical Systems, a member of the Roche Group, have collaborated for the development and commercialisation of a pan-TRK immuno-histochemistry (IHC) test.

Loxo Oncology and Ventana Medical Systems, a member of the Roche Group, have collaborated for the development and commercialisation of a pan-TRK immuno-histochemistry (IHC) test.

The test will be used as a companion diagnostic to identify patients across tumour types suitable for treatment with larotrectinib.

The partnership will use Loxo Oncology’s investigational assay, which will be further developed by Roche using its flagship OptiView DAB detection technology. An analytical assay will be globally commercialised, following which the companies will develop a Class III assay for pre-market approval (PMA) from the US FDA.

"Roche will be responsible for obtaining regulatory approvals for the companion diagnostic test in the US and other countries in the EU."

Roche will be responsible for obtaining regulatory approvals for the companion diagnostic test in the US and other countries in the EU.

Merit Medical Systems intends to raise $125m through a public offering of its common stock shares. The company also offers a 30-day option for the underwriters to purchase an additional $18.75m shares.

The proceeds from the offering will be used by the company to repay debt under its existing credit facility and to invest in short-term, investment-grade, interest-bearing securities.

In-vitro diagnostics company, BioMaxima, and Pure Biologics have signed an agreement to commercialise the results of the latter’s research and development related to the new tools for in-vitro diagnostics.

The two companies will initiate research projects, as part of the agreement. While the former will be responsible for testing, the latter will be involved in the development of technologies.

Medical technology company, Symetis, intends to raise gross proceeds of €55.8m ($59.9m) through a public placement of its common stock shares. The company has also announced an over-allotment option of up to 15% of the number of new shares offered.

The proceeds from the offering, which will be closed on 28 March 2017, will be used for the internal development of new products, to expand manufacturing capacity, acquire synergistic technologies or products and for other working capital requirements.

Kailos Genetics has signed a co-marketing agreement with Illumina to commercialise the former’s line of research solutions for pharmacogenetics targets.

Illumina will use its commercial channels to market and promote Kailos’ research solutions including TargetRich PGxComplete and Kailos Blue.